UNH Beats, ELV Drops!! - What I'm doing NOW...
2 extracted signals · 2 resolved · 0 still active
Deep Value HunterIndependent analyst profile- Source published
- 18 Jul 2026, 16:30 UTC
- Recorded by Tahlil Plus
- 10 Aug 2026, 16:32 UTC
AI-generated source summary
The analysis covers two healthcare stocks, UNH and ELV. For UNH, the base case forecast suggests a 9% IRR with flat revenue growth and a 12x EV/EBIT multiple, implying a target fair value of $400. However, the analysis indicates that at its current price of $423.38, UNH may be overvalued, and the presenter is looking to exit their position. For ELV, the base case projects a 18% IRR with 7% revenue growth and a 6.5% operating margin, leading to a fair value of $509.7. The presenter finds ELV to be reasonably priced with a good risk-reward profile, suggesting holding the stock. The analysis also touches on the importance of considering the broader market context when evaluating individual stocks, particularly in the healthcare sector.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Deep Value Hunter
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.